SCHEMBL3143606

SCHEMBL3143606

CCOC(=O)CCc1ccc(Oc2ccc(/C=C/c3ccc(C(F)(F)F)cc3)cn2)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.44
FFAR1 O14842 1/20 0.42
FFAR2 O15552 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
PPARA Q07869 4/20 0.42
PPARD Q03181 2/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
HPGD P15428 1/20 0.41
DPP4 P27487 1/20 0.41
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
DRD2 P14416 1/20 0.40
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711387 0.90 PPARA (0.52) MMP1FFAR1FFAR2FFAR4PPARA
SCHEMBL4711388 0.90 PPARA (0.52) MMP1FFAR1FFAR2FFAR4PPARA
SCHEMBL3134846 0.86 PPARA (0.44) FFAR1FFAR2FFAR4PPARAPPARD
SCHEMBL3142944 0.85 GPBAR1 (0.40) FFAR1FFAR2FFAR4PPARAPPARD
SCHEMBL3142600 0.84 CDK8 (0.46) MAPTLMNADRD2KMT2ASMN1; SMN2
SCHEMBL3142604 0.84 CDK8 (0.46) MAPTLMNADRD2KMT2ASMN1; SMN2
SCHEMBL5167452 0.83 PDE2A (0.43) FFAR1FFAR2FFAR4PPARAPPARD
SCHEMBL3143612 0.81 PPARA (0.64) MMP1PPARAPPARDPSEN1PSEN2
SCHEMBL3142584 0.81 CYP19A1 (0.43) DPP4MAPTLMNADRD2KMT2A
SCHEMBL3138732 0.81 DRD2 (0.45) MAPTLMNADRD2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 MMP1 3453/4885FFAR1 865/4885FFAR2 2364/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 MMP1 213/4885FFAR1 1139/4885FFAR2 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.